Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IMO Schwartz stock sales may be the key that unravels this conundrum
Reply New Message
Prev Message Back To Forum Threaded View Next Message

So... Instead of taking what PTSC's CEO stated.. that all the licensing revs for that period were reported/included in that Q (and that there may be something of additional value sealed in the CC and enforcable by the MOU) .. The T3 are going to be convinced to ante up big $$ by having to take PTSC's next 4 or 5 (6, 7?) Qs and dig out the recurring payments the Js are going to make...

Or do you think the T3 took the initiative to file ADRs first in NDCa, after 1-2 yrs of negotiations, because TPL was going to share with them what the Js paid?

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply